WTI crude oil triggered a bullish reversal after testing support at $91.20, reaching a high of $96.25. This support level is crucial, as a drop below it could lead to further declines toward $88.64 and $86.01. Resistance is expected near the 20-day moving average at $97.41 and the recent high of $97.68, with a decisive break above $97.68 potentially targeting $100.43. The weekly chart also signals a possible bullish reversal if this week's high is surpassed, but the overall bearish trend remains until clear strength emerges.
WTI crude oil price forecast shows a bullish reversal testing key resistance. For readers following US stocks, here is Pluang's market snapshot as of Oct 02, 2026 03:41 WIB: of 150 priced US stocks, 72 rose and 78 fell. Notable movers include IQ at USD 0.99 (-3.94%), AMAT at USD 528.65 (+3.38%), and DIS at USD 101.44 (-3.31%).
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
